Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and

impact on mortality: a systematic review

Alice Liu[1], Adelaide Dennis[1], Zarin Fariha[1], Rekha Pai Mangalore[1], Nenad Macesic*[1,2,3]

Affiliations

[1] Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,

Monash University, Melbourne, Australia

[2] Centre to Impact AMR, Monash University, Clayton, Australia

[3] Infection Prevention & Healthcare Epidemiology, Alfred Health, Melbourne, Australia.

* Corresponding Author

Dr. Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of

Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55

Commercial Rd, Melbourne, VIC 3004, Australia. Email: nenad.macesic1@monash.edu

Word count (excluding abstract): 2465

Abstract (280 words)

Background: Bloodstream infections (BSI) cause significant morbidity and mortality in solid organ transplant (SOT) recipients. There are few data regarding the contribution of multidrug-resistant organisms (MDROs) to these infections.

Objectives: We evaluated the resistance-percentage of MDRO BSIs in SOT recipients and assessed associated mortality.

Methods: A systematic review

Data sources: MEDLINE and Embase databases up to January 2024.

Study eligibility criteria: Studies of adult SOT recipients that quantify MDRO BSI resistance-percentage and/or associated crude mortality. MDROs studied were carbapenem-resistant Enterobacterales (CRE), *Acinetobacter baumannii* (CRAB) and *Pseudomonas aeruginosa* (CRPA), third-generation-cephalosporin-resistant Enterobacterales (3GCR-E), methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium* (VRE).

Participants: Adult SOT recipients with a microbiologically confirmed BSI.

Interventions: Not applicable.

Risk of bias assessment: Newcastle Ottawa Scale.

Methods of data synthesis: MDRO BSI resistance-percentage and mortality outcomes were reported as median (IQR) and crude mortality (%), respectively.

Results: Of 945 studies identified, 52 were included. Most were retrospective (41/52) and/or single centre (37/52), and liver transplantation was the most studied SOT type (22/52). High resistance-percentages of BSIs were noted, ranging from 13.6% CRE for Enterobacterales to 59.2% CRAB for *Acinetobacter baumannii*. Resistance-percentage trends decreased over time, but these changes were not statistically significant. Asia had highest resistance-percentages for MRSA (86.2% [IQR 77.3-94.6%]), 3GCR-E (59.5% [IQR 40.5-66.7%]) and CRE (35.7% [IQR 8.3-63.1%]). North America had highest VRE resistance-percentages (77.7% [IQR 54.6-94.7%]). Crude mortality was 15.4-82.4% and was consistently higher than non-MDRO BSIs.

Conclusions: MDRO BSIs resistance-percentages were high for all pathogens studied (IQR 24.6-69.4%) but there was geographical and temporal heterogeneity. MDRO BSIs were associated with

46   high mortality in SOT recipients. Microbiological and clinical data in this vulnerable population were

47   incomplete, highlighting the need for robust international multi-centre studies.

Introduction

Solid organ transplantation (SOT) provides a life-saving measure for patients with end-stage organ

failure. However, SOT recipients are at increased susceptibility to infection, which may result in

impaired graft function and adverse outcomes (1). Bloodstream infections (BSI) are a leading cause

of morbidity and mortality in this population (2-5), with mortality reaching 50% when associated with

septic shock (5, 6). Post-transplant BSIs result in prolonged hospital stays, need for re-admission

and substantial financial costs (4). Infections with multidrug-resistant organisms (MDROs) are

common among SOT recipients due to extended exposure to broad spectrum antimicrobials,

immunosuppressive medications, presence of chronic indwelling devices and frequent healthcare

exposure (7, 8). SOT itself has been described as an independent risk factor for certain MDRO

infections (8). MDRO infections are associated with greater mortality and increased risk of graft

failure than those caused by susceptible pathogens (7, 9, 10), posing a major challenge to individual

patient care. Furthermore, antimicrobial treatment options for these organisms are often limited and

may come with significant toxicities and cost.

While there are multiple reports of high resistance rates and poor outcomes of BSIs in SOT

recipients (7, 11-13), there remains an urgent need to better understand the epidemiology and

temporal trends in these infections. In the absence of prior systematic review data, we provide a

comprehensive description of MDRO BSI resistance-percentages and associated mortality in SOT

recipients, focusing on clinically relevant pathogens that influence empirical and directed

antimicrobial decision making. The MDROs studied in this review represent a critical group of

pathogens that pose a significant global public health threat and are common causes of life-

threatening hospital-acquired infection (14).

Methods

Study selection

We performed a systematic review of all published literature describing resistance-percentage

and/or mortality of BSIs due to MDROs among adult SOT recipients. Six MDROs were selected

from the WHO Bacterial Priority Pathogens (2024 update) due to their relevance for SOT recipients (15): carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant *Acinetobacter baumannii* (CRAB), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), third generation cephalosporin-resistant Enterobacterales (3GCR-E), vancomycin-resistant *Enterococcus faecium* (VRE) and methicillin-resistant *Staphylococcus aureus* (MRSA).

We included all published studies (retrospective and prospective) of adult (≥18 years) SOT recipients (heart, lung, liver, kidney, pancreas, intestinal and multivisceral) that quantified BSIs due to MDROs and/or associated crude mortality rates. Additional studies were identified from review of reference lists. Only full text studies were included in the analysis. Case reports, expert opinion pieces, narrative reviews, pharmacokinetic/pharmacodynamic studies, and studies of colonisation or surveillance blood cultures were excluded. Studies that lacked quantitative data of the proportion of BSIs due to MDROs were also omitted.

The primary outcome was proportion of BSIs due to MDROs, expressed as median [IQR]. The secondary outcome was crude mortality due to MDRO BSI, expressed as a proportion (%).

Search strategy

A literature search was conducted in the Embase and MEDLINE databases in accordance with guidelines from the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement (16). No time or language restriction was applied. The following key words and their related MeSH and Emtree search terms were used in various combinations: bloodstream infection, bacteraemia, sepsis, solid organ transplantation, organ graft, multidrug-resistant organism, antimicrobial resistance, carbapenem resistance, extended-spectrum beta-lactamase, vancomycin resistance, methicillin resistance, Enterobacterales, Acinetobacter, Pseudomonas, Staphylococcus and Enterococcus. Full search strategy results are provided in Supp. Tables 1 and 2. The study was registered with PROSPERO (CRD42023466931).

<u>Data extraction and analysis</u>

Title and abstract screening were performed by AL. Full text screening was performed by three

reviewers (AL, AD, ZF), who also extracted data independently. Conflicts between reviewers on

eligibility assessments and data extraction results were resolved through discussion and consensus

among all authors. Duplicate studies were removed via Covidence systematic review software

(Veritas Health Innovation, Melbourne, Australia) and manual checking. Data were extracted using a

custom extraction template covering the following variables: study design, year and location, study

population size, type/s of transplant, MDRO species and their frequency, associated crude mortality

(where available) and antimicrobial susceptibility testing methods. Statistical analyses and

visualisations were performed with R v4.3.0 (2023). Specifically, we applied a linear regression

analysis using the 'lm' function to assess the presence of a trend in MDRO resistance-percentages

over time.

<u>Risk of bias assessment</u>

Quality assessment was conducted using the Newcastle Ottawa Scale (NOS) (17). For the NOS

assessment, exposure was defined as BSI due to MDRO. Comparability of cohorts was based on

controlling for baseline patient demographics and immunosuppression regimen. Assessment of

MDRO proportions was through microbiological confirmation with a description of the antimicrobial

susceptibility methods included. Assessment of mortality outcomes was through an independent

assessment or record linkage. There was no minimum follow-up period, and the shortest study

period was 12 months (18). Studies with a NOS score of 7 or greater were included in the final

analysis.

Results

Study characteristics

A total of 1137 studies were identified. After removal of duplicates, 945 were screened, of which 114

studies were retrieved and 52 included in the final analysis (Fig. 1). Reasons for exclusion (62

studies) were incorrect study design, outcomes not specific to BSIs or insufficient data on

antimicrobial susceptibility. Most studies were retrospective (41/52, 78.8%) and single-centre (37/52,

71.2%). Of the studies focused on a single transplant type, liver transplant was the most studied

(22/52, 42.3%), followed by kidney transplant (5/52, 9.6%). Eighteen (34.6%) studies included

pooled multiple transplant types in their analysis. Study population size was variable, ranging from

14 BSI episodes over a 3-year period (19) to 988 episodes over 10 years (8). Full details on the

characteristics of the included studies are provided in Supp. Table 3. Quality assessment using the

NOS is described in Supp. Tables 4 and 5.

Pooled estimates of MDRO BSIs in SOT recipients

Proportion of BSIs due to MDROs was reported in 49/52 studies with only crude mortality reported

in the remaining three studies. MDRO BSI resistance-percentages are shown in Table 1 and Fig. 2A

and ranged from 13.6% (IQR 8.7-37.0%) carbapenem resistance in Enterobacterales to 59.2% (IQR

50.0-77.4%) carbapenem resistance in *Acinetobacter baumannii*. We analysed MDRO resistance-

percentages over time and noted reducing trends for all MDROs except CRAB, but these changes

were not statistically significant (Table 1, Fig. 2B and Supp. Table 6).

MDRO BSI resistance-percentage varied by region (Table 1), with Asia having highest median

resistance-percentages of MRSA (86% [IQR 77-95%]), 3GCR-E (60% [IQR 40-67%]), CRE (36%

[IQR 8-63%]) and CRAB (60% [IQR 54-89%]). North America had highest VRE resistance-

percentages (median 78% [IQR 55-95%]). South America had highest CRPA resistance-percentage

(88%), but this was based on results of a single study.

Liver transplantation was the most studied transplant type with the following median MDRO

resistance-percentages: CRE 9.5% (IQR 4.7-14.3%), 3GCR-E 40.4% (IQR 26.7-59.5%), CRAB

72.3% (IQR 48.2-93.3%), CRPA 33.3% (IQR 9.1-5.7%), VRE 34.0% (IQR 24.3-69.8%) and MRSA

80.0% (IQR 48.7-96.4%). Kidney transplantation had sufficient data for analysis of 3GCR-E

resistance-percentage (median 32.4% [IQR 21.1-65.3%]), but there were too few studies to

determine these for other transplant type/MDRO combinations.

<u>Pooled estimates of mortality due to MDRO BSI in SOT recipients</u>

Mortality associated with MDRO BSI was reported in 17/52 (32.7%) studies (Table 2). The method

of reporting varied between studies, including different time intervals. In most studies (13/17, 76.5%)

mortality was recorded by attributable organism, however 3 studies pooled multiple MDRO

pathogens for mortality outcomes. Within these limits, crude mortality due to MDRO BSI ranged

from 15.4% (VRE 30-day mortality in liver transplant recipients) (20) to 82.4% (CRE mortality in liver

transplant recipients admitted to intensive care) (21). Excluding patients in the intensive care

setting, crude mortality remained as high as 65.5% (CRAB 10- and 30-day mortality in liver

transplant recipients) (22). Where mortality due to MDRO BSI was assessed alongside drug-

susceptible BSI, MDRO BSIs were consistently associated with a higher mortality rate irrespective

of MDRO or transplant type (Table 2). For individual MDROs, MRSA and VRE-associated mortality

were most frequently reported, with a median crude mortality of 36.1% (IQR 19.3–56.3%) and

37.2% (IQR 30.9-42.5%), respectively. There was insufficient data for pooled analysis for all other

MDROs studied.

Discussion

Our systematic review aimed to quantify the burden of MDRO BSIs in SOT recipients and

successfully consolidated global antimicrobial resistance (AMR) data for multiple clinically relevant

pathogens that cause BSIs in SOT recipients. We observed high resistance-percentages for BSIs in

SOT recipients, ranging from median 13.6% for CRE BSIs to median 56.2% for CRAB BSIs.

However, there was considerable heterogeneity in resistance-percentages across different regions

and time periods. While there were decreasing trends in MDRO BSIs over time, CRAB remained an

exception. MDRO BSIs were associated with high crude mortality in SOT recipients, ranging from

15% up to 82.4% in one study in an intensive care setting (21).

We noted prominent differences in MDRO BSI burden across regions. A key question arises

regarding comparison with AMR burden in the general population. Asia had highest resistance-

percentages for multiple pathogens (MRSA, 3GCR-E, CRE and CRAB). These were higher than in

the general hospitalised population in Asia (30.5-49.0% for MRSA BSIs, 36.0-57.2% for 3GCR-E

BSIs and 23.1-26.1% for CRE BSIs) (23, 24) but lower for CRAB BSIs (median 60% in SOT

recipients vs. 71.5-90.5%) (23, 24). Most Asian studies were confined to liver transplant, which is

more commonly associated with post-operative bacterial infections (25-27). This, combined with

high overall rates of AMR in many Asian countries may explain the high resistance-percentages for

BSIs in SOT recipients we observed in this region (23, 28, 29). North America exhibited the highest

resistance percentage of VRE (median 76.6%), aligning with surveillance data demonstrating >70%

of US hospital *Enterococcus faecium* isolates are VRE (30). Conversely, Europe had the lowest

VRE resistance-percentages (median 3.0%). European general VRE surveillance data range widely

from <1% in Holland to 45% in Greece (31). In our review, Spanish (4/16, 25%) and Italian studies

(4/16, 25%) were most frequently represented, and our VRE findings reflected surveillance data

rates from both countries (3% and 11%, respectively) (31).

Resistance-percentages decreased over time for several of the pathogens studied (MRSA, VRE,

3GCR-E, CRE and CRPA). While these trends did not reach statistical significance, this finding

contrasts to global observations of increasing MDRO prevalence over time (32-35). MRSA is unique

in demonstrating an early rise and subsequent fall in its prevalence across multiple geographic

regions over the last two decades (36), potentially explaining our findings of reducing MRSA trends.

The decreasing prevalence of other MDROs over time may potentially be attributed to

improvements in infection control measures, better detection of donor-derived infections and

changes in antibiotic prophylaxis prescribing practices over time (37, 38). Furthermore, global AMR

surveillance methods are not standardised nor is coverage universal (39), and the resistance-

percentage rates noted in this study represent specialised transplant centres rather than all

healthcare facilities. In contrast, we noted increasing CRAB resistance-percentages in our study,

which may reflect the contribution of frequent intensive care unit admission following SOT, with

healthcare-associated horizontal transmission of CRAB well described in this setting (40, 41).

We found high crude mortality rates among patients with MDRO BSIs ranging from 15.4 to 82.4%.

However, this was based on limited data (17 studies), with almost all studies reporting on <100 SOT

recipients with MDRO BSI. These findings contrast with prior reports that noted lower mortality in

SOT recipients with sepsis in the early post-transplant period than in non-SOT patients (42, 43).

However, these studies did not distinguish between BSI with susceptible and drug-resistant

pathogens. Even fewer studies (n=4) compared mortality between MDRO and non-MDRO BSIs in

SOT recipients, but in these studies MDRO BSIs were consistently associated with a higher crude

mortality rate (10, 20, 44, 45). This may reflect use of empiric antibiotics with inadequate spectra of

activity. Alterations in the pathophysiology of different SOT recipients may also account for the high

overall mortality rate in this population. For example, heart transplant recipients have higher risk of

cardiogenic shock complicating septic shock, while lung transplant recipients are at greater risk of

respiratory failure requiring intubation and intensive care support (46).

Our study has several limitations. Firstly, the included studies were heterogeneous in their

population size and follow-up period. It was therefore not feasible to conduct a meta-analysis of the

study outcomes. The transplant type strongly influences the primary site of infection and associated

sepsis (47). We were unable to stratify MDRO frequency-percentages by transplant type because

many studies pooled multiple transplant types in their analyses. Additionally, data on prescribing

practices were inconsistently recorded across studies and there is a high likelihood that there were

geographical and temporal differences in therapeutic and prophylactic antimicrobial prescribing and

immunosuppression regimens. These differences would influence MDRO BSI frequency-

percentages observed. Finally, mortality data were not reported in a standardised manner, varying

from 5-day to 1-year mortality figures, limiting pooled analysis and comparison between studies.

Our review underscores several priorities in the care of SOT recipients. Our findings of high

resistance-percentages for BSIs and significant associated mortality highlight that prevention of

MDRO acquisition remains paramount. This includes but is not limited to proactive antimicrobial

stewardship pre- and post-transplantation to reduce selection pressure, infection control measures

to limit cross-transmission in hospital settings, and regular review of immunosuppressant

medications and indwelling devices to reduce the risk of colonisation. Strategies for early

identification of BSIs caused by MDROs may also help in timely antibiotic rationalisation and limiting

the emergence of MDROs in the transplant population, such as continued development of rapid

laboratory diagnostics and antimicrobial susceptibility testing methods, and implementation of

protocolised surveillance testing programs for donors and recipients.

We also identified future research priorities. Our review found a paucity of transplant type-specific

microbiological data, non-standardised mortality reporting methods and a reliance on retrospective

and/or single centre data resulting in wide variation in study size. It has been noted that frequency

measures such as resistance-percentages are of limited use without accompanying population

resistance-percentage estimates or incidence-density data (48), which was also evident in our

review. Future work should focus on longitudinal prospective data collection using consistent

metrics, capturing both clinical and microbiological outcomes and representing SOT types

proportionately. This presents an opportunity to further develop and implement larger scale

transplant registries such as the Swiss Transplant Cohort study (11, 13) which capture infectious

complications and corresponding microbiological data.

Conclusion

Our findings reinforce that SOT recipients are highly vulnerable to MDRO BSIs and experience

substantial associated mortality. We identified marked geographical variation in the proportion of

MDRO BSIs, which warrants ongoing characterisation in future studies. While there was a trend

towards reducing resistance-percentages of several MDROs, this was not statistically significant

and certain pathogens were under-represented. We noted gaps in the reporting of transplant type-

specific data and a paucity of standardised mortality outcomes. Our study highlights the urgent need

for robust international multi-centre cohort studies that adequately capture microbiological data and

BSI clinical outcomes to guide prevention and empirical treatment strategies in this highly

vulnerable patient group.

References

1.   Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-14.

2.   Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, 3rd, et al. Bloodstream infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016-21). JAC Antimicrob Resist. 2024;6(1):dlad158.

3.   Gavalda J, Aguado JM, Manuel O, Grossi P, Hirsch HH, Hosts ESGoIiC. A special issue on infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:1-3.

4.   Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence. 2016;7(3):329-40.

5.   Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc. 2005;37(9):4097-9.

6.   Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007;7(11):2579-86.

7.   Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, III, et al. Bloodstream infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016–21). JAC-Antimicrobial Resistance. 2024;6(1).

8.   Anesi JA, Lautenbach E, Tamma PD, Thom KA, Blumberg EA, Alby K, et al. Risk Factors for Extended-Spectrum beta-lactamase-Producing Enterobacterales Bloodstream Infection Among Solid-Organ Transplant Recipients. Clin Infect Dis. 2021;72(6):953-60.

9.   Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, et al. External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infect Dis. 2019;6(4):ofz110.

10.   Anesi JA, Lautenbach E, Thom KA, Tamma PD, Blumberg EA, Alby K, et al. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients. Transplantation. 2023;107(1):254-63.

11.   van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al. Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study. Clin Infect Dis. 2020;71(7):e159-e69.

12.   Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis. 2014;16(5):767-74.

13.   Neofytos D, Stampf S, Hoessly LD, D'Asaro M, Tang GN, Boggian K, et al. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update. Open Forum Infect Dis. 2023;10(6):ofad247.

14.   Parker MT, Organization WH. Hospital-acquired infections: guidelines to laboratory methods: World Health Organization. Regional Office for Europe; 1978.

15.   WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva; 2024.

16.   Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

17.   Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

18.   Gagliotti C, Morsillo F, Moro ML, Masiero L, Procaccio F, Vespasiano F, et al. Infections in liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis. 2018;37(3):399-407.

19.   Karruli A, de Cristofaro J, Andini R, Iossa D, Bernardo M, Amarelli C, et al. Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center Experience. Microorganisms. 2021;9(6).

20.   Dubler S, Lenz M, Zimmermann S, Richter DC, Weiss KH, Mehrabi A, et al. Does
vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver
transplantation? A retrospective study. Antimicrob Resist Infect Control. 2020;9(1):22.
21.   Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, et al.
Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among
intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact
of resistance on outcomes. Transplant Proc. 2014;46(9):3216-8.
22.   Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et al. Incidence, mortality, and risk
factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days
after liver transplantation. Clin Transplant. 2023;37(5):e14956.
23.   Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, et al. Current status and trends of
antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from
2018 to 2022. One Health Advances. 2023;1(1):8.
24.   Kim D, Yoon EJ, Hong JS, Choi MH, Kim HS, Kim YR, et al. Major Bloodstream Infection-
Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase
I Report From Kor-GLASS. Front Microbiol. 2021;12:799084.
25.   Kim SI. Bacterial infection after liver transplantation. World J Gastroenterol.
2014;20(20):6211-20.
26.   Kim SH, Mun SJ, Ko JH, Huh K, Cho SY, Kang CI, et al. Poor outcomes of early recurrent
post-transplant bloodstream infection in living-donor liver transplant recipients. Eur J Clin Microbiol
Infect Dis. 2021;40(4):771-8.
27.   Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, et al. Infectious complications in living-
donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis.
2008;10(5):316-24.
28.   Qiao M, Ying GG, Singer AC, Zhu YG. Review of antibiotic resistance in China and its
environment. Environ Int. 2018;110:160-72.
29.   Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents.
2011;37(4):291-5.
30.   CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department
of Health and Human Services, CDC; 2019.
31.   Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence
and spread of vancomycin resistance among enterococci in Europe. Eurosurveillance.
2008;13(47):19046.
32.   Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant
Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy.
Microbiol Res. 2023;266:127249.
33.   Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing
Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47):19044.
34.   Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus
(MRSA) (%) [Internet]. WHO. 2024. Available from: https://data.who.int/indicators/i/5dd9606.
35.   Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, et al. Comparison of the global
prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between
healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist.
2022;4(3):dlac048.
36.   Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-Year Trends in
Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial
Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S47-s53.
37.   Smibert O, Satlin MJ, Nellore A, Peleg AY. Carbapenem-Resistant Enterobacteriaceae in
Solid Organ Transplantation: Management Principles. Curr Infect Dis Rep. 2019;21(7):26.
38.   Nellore A, Huprikar S, Practice AICo. Vancomycin-resistant Enterococcus in solid organ
transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases
Community of Practice. Clin Transplant. 2019;33(9):e13549.
39.   WHO. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.
40.   Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter
baumannii: A challenge in the intensive care unit. Front Microbiol. 2022;13:1045206.

41.   Doughty EL, Liu H, Moran RA, Hua X, Ba X, Guo F, et al. Endemicity and diversification of
carbapenem-resistant Acinetobacter baumannii in an intensive care unit. Lancet Reg Health West
Pac. 2023;37:100780.
42.   Donnelly JP, Locke JE, MacLennan PA, McGwin G, Jr., Mannon RB, Safford MM, et al.
Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe
Sepsis. Clin Infect Dis. 2016;63(2):186-94.
43.   Kalil AC, Syed A, Rupp ME, Chambers H, Vargas L, Maskin A, et al. Is bacteremic sepsis
associated with higher mortality in transplant recipients than in nontransplant patients? A matched
case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216-22.
44.   Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of
bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.
Transplantation. 2013;96(9):843-9.
45.   Ye QF, Zhou W, Wan QQ. Donor-derived infections among Chinese donation after cardiac
death liver recipients. World J Gastroenterol. 2017;23(31):5809-16.
46.   Eichenberger EM, Ruffin F, Sharma-Kuinkel B, Dagher M, Park L, Kohler C, et al. Bacterial
genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus
bacteremia. Transpl Infect Dis. 2021;23(6):e13730.
47.   Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early
bacteremia after solid organ transplantation. Transplant Proc. 2009;41(6):2262-4.
48.   Pezzani MD, Arieti F, Rajendran NB, Barana B, Cappelli E, De Rui ME, et al. Frequency of
bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research
and discovery of new therapies in Europe: a systematic review. Clin Microbiol Infect. 2024;30 Suppl
1:S4-S13.

Fig. 1: PRISMA flow diagram

Fig. 2: Comparison of proportions of bloodstream infections caused by multidrug-resistant organisms in solid organ transplant recipients by included study

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

Table 1: Proportions of bloodstream infections caused by resistant organisms in solid-organ transplant recipients by time period and region

	Pooled (n = 49)	2002 – 2010 (n = 10)	2011 – 2015 (n = 15)	2016 – 2020 (n = 12)	2021 – 2024 (n = 12)	Europe (n = 16)	North America (n = 12)	South America (n = 4)	Asia (n = 17)
3GCR-E, median (IQR) (% of Enterobacterales)	38.2% (27–49%)	42.3% (33.6–50.9%)	30.0% (27.6–56.5%)	33.8% (20.8–40.8%)	40.0% (35.0–47.5%)	29.3% (21.2–40.5%)	33.5% (30.4–36.2%)	43.4% (41.9–44.9%)	63.1% (45.2–72.9%)
CRE, median (IQR) (% of Enterobacterales)	13.6% (8.7–37.0%)	9.5%*	45.5%*	28.6% (14.3–61.9%)	6.3% (3.6–9.1%)	14.3%*	12.9% (7.8–13.6%)	NR	35.7% (8.3–63.1%)
CRAB, median (IQR) (% of *A. baumannii*)	59.2% (50.0–77.4%)	60.0%*	54.2% (48.2–73.3%)	72.4% (6.2–83.6%)	84.6%*	50.0% (50.0–61.4%)	NR	53.6% (42.9–64.3%)	60.0% (54.2–88.7%)
CRPA, median (IQR) (% of *P. aeruginosa*)	33.3% (24.3–43.8%)	NR	33.3% (33.3–74.3%)	32.4% (27.9–36.8%)	17.0% (6.8–29.9%)	45.2% (25.0–61.4%)	38.9% (36.1–41.7%)	87.5*	27.5% (21.0–32.8%)
MRSA, median (IQR) (% of *S. aureus*)	50.4% (36.4–86.7%)	77.8% (47.40–100%)	56.0% (35.5–84.3%)	77.9% (73.9–81.8%)	31.5% (15.6–47.4%)	31.7% (22.0–46.6%)	50.5% (38.1–77.8%)	64.3% (53.6–75.0%)	86.2% (77.3–94.6%)
VRE, median (IQR) (% of *E. faecium*)	38.1% (3.0–67.6%)	55.6% (27.88–77.8%)	15.0% (0.0–36.1%)	53.0% (28.4–76.0%)	36.9% (8.9–62.2%)	3.0% (0.0–23.5%)	76.6% (57.2–89.4%)	38.6%*	32.3% (6.6–51.2%)

*only single studies available, unable to calculate IQR. NR = not reported.

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

Table 2: Mortality due to bloodstream infection from multidrug resistant organism/s in solid organ transplant recipients:

Author	Year	Location	Study characteristics	Study population characteristics including SOT type	Organism/s studied	Mortality
Singh et al.	2004	United States	Retrospective, single centre, observational study	233 liver transplant recipients between 1989 – 2003	MRSA VRE	MRSA mortality 9/33 (27.3%) VRE mortality 4/8 (50.0%)
Husain et al.	2006	United States	Prospective, multicentre, observational study (4 sites)	56 lung transplant recipients with bacteraemia between July 2000 – February 2004	MRSA	MRSA mortality 1/6 (16.7%)
Bedini et al.	2007	Italy	Retrospective, single centre, observational study	205 liver transplant recipients between October 2000 - September 2005	MRSA	MRSA 30-day mortality 3/5 (60.0%)
Kim et al.	2009	Korea	Retrospective, single centre, observational study	144 liver transplant recipients between January 2005 – September 2007	MRSA VRE ESBL CRAB CRPA	VRE mortality 2/5 (40.0%)
Bodro et al.	2013	Spain	Prospective, single centre, observational study	190 SOT recipients (liver, kidney and heart) between January 2007 – December 2012	MRSA VRE 3GCR-E CRAB CRPA	Pooled MDRO mortality 19/54 (35.2%) Pooled non-MDRO mortality 32/185 (14.4%)
Aguiar et al.	2014	Brazil	Retrospective, single centre, observational study	759 kidney and 258 liver transplant recipients between January 2000 – September 2008	3GCR-E	ESBL 30-day mortality 10/39 (25.6%)

Mouloudi et al.	2014	Greece	Prospective, single centre, observational study	17 Liver transplant recipients admitted to the intensive care unit between January 2008 – December 2011	CRE (CRKP only)	CRKP mortality 14/17 (82.4%)
Ye et al.	2014	China	Retrospective, multicentre, observational study (2 sites)	71 SOT recipients between January 2002 – August 2013	MRSA VRE 3GCR-E CRE CRAB	Pooled MDRO 30-day mortality 22/39 (56.4%) Pooled non-MDRO 30-day mortality 12/32 (37.5%)
Zhou et al.	2015	China	Retrospective, multicentre, observational study (2 sites)	275 liver transplant recipients with *S. aureus* BSI between January 2001 – December 2014	MRSA	MRSA mortality 9/20 (45.0%)
Kim et al.	2018	Korea	Retrospective, single centre, observational study	393 liver transplant recipients from January 2008 – April 2015	CRAB	CRAB 1-year mortality 5/14 (35.7%)
Kim et al.	2019	Korea	Retrospective, single centre, observational study	536 liver transplant recipients between January 2008 – December 2017	VRE	VRE 1-year mortality 9/25 (36.0%)
Dubler et al.	2020	Germany	Retrospective, single centre, observational study	177 liver transplant recipients between January 2006 – December 2016 who had an E. faecium bacteraemia	VRE	VRE 30-day mortality 6/39 (15.4%) VRE 90-day mortality 15/39 (38.5%) Non-VRE 30-day mortality 15/138 (10.9%) Non-VRE 90-day mortality 43/138 (31.2%)

Mercuro et al.	2020	United States	Retrospective, single centre, cohort study	58 hospitalised SOT recipients (3 heart, 3 lung, 33 liver, 6 kidney, 10 intestinal, 3 multivisceral) with E faecium BSI between January 2013 – February 2019	VRE	VRE mortality - 13/41 (31.7%)
Kim et al.	2021	Korea	Retrospective, single centre, observational study	727 liver transplant recipients between January 2008 – December 2016	MRSA VRE 3GCR-E CRE CRAB CRPA	Pooled MDRO 90-day mortality 15/39 (38.5%)
Lee et al.	2022	US	Retrospective, multicentre, cohort study	117 liver transplant recipients (including 22 multivisceral) between January 2006 – December 2016	VRE	VRE 1-year mortality 29/108 (26.9%)
Anesi et al.	2023	United States	Retrospective, multicentre, cohort study	897 SOT recipients (69 episodes of heart transplant, 58 lung, 278 liver, 514 kidney, 27 pancreas) with an Enterobacterales BSI between 2005 – 2018	CRE	CRE 60-day mortality 33/70 (47.1%) Non-CRE 60-day mortality 102/827 (12.3%)
Min et al.	2023	Korea	Retrospective, single centre, nested case control study	1051 liver transplant recipients between September 2005 – December 2021	CRAB	CRAB 5-day mortality 17/29 (58.6%) CRAB 10-day mortality 19/29 (65.5%) CRAB 30-day mortality 19/29 (65.5%)

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales, BSI – bloodstream infection, CRAB – carbapenem-resistant *Acinetobacter baumannii*, CRE – carbapenem-resistant Enterobacterales, CRKP – carbapenem-resistant *Klebsiella pneumoniae*, CRPA – carbapenem-resistant *Pseudomonas aeruginosa*, MDRO – multi-drug resistant organism/s, MRSA – methicillin-resistant *Staphylococcus aureus*, SOT – solid organ transplant, VRE – vancomycin-resistant *Enterococcus faecium*.